{
    "initial_input_text": "# Ontologist Analysis\n                    {\n                    ### Definitions:\n                    - **Inflammation**: A biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It involves immune cell activation, blood vessel dilation, and the release of various molecules that promote healing.\n                    - **Amyloid Beta**: A peptide that is produced in the brain through the breakdown of a larger protein called amyloid precursor protein (APP). Accumulation of amyloid beta in the brain is commonly associated with neurodegenerative diseases, especially Alzheimer's disease.\n                    - **Alzheimer's Disease**: A progressive neurological disorder characterized by cognitive decline, memory loss, and changes in behavior and personality. It is associated with the accumulation of amyloid beta plaques and neurofibrillary tangles in the brain.\n\n                    ### Relationships\n                    - **Inflammation increases Amyloid Beta**: This relationship indicates that the presence of inflammation in the brain can lead to an increase in the production or aggregation of amyloid beta peptides. This connection suggests that inflammatory processes might play a crucial role in the pathogenesis of Alzheimer's disease by enhancing the toxic effects of amyloid beta.\n                      \n                    - **Amyloid Beta accumulates in Alzheimer's Disease**: This relationship illustrates how the accumulation of amyloid beta is a defining feature of Alzheimer's disease. In patients with Alzheimer’s, there is a significant build-up of amyloid beta plaques in the brain, which is believed to contribute to the neurodegenerative processes observed in the disorder, such as synaptic dysfunction and neuronal death.\n                    }",
    "web_search_results": [],
    "scientific_literature_results": [
        {
            "title": "The potential of novel gut microbiota supplement in mitigating gut inflammation, alleviating oxidative stress linked to aging, and improving cognitive function in aged mice.",
            "authors": [
                "Kaikwa Wuttisa",
                "Pol Sookpotarom",
                "Benjamaporn Poopan",
                "Chantanapa Chantarangkul",
                "Praewpannarai Jamjuree",
                "Jirapat Namkeaw",
                "Thiranut Jaroonwitchawan",
                "Malai Taweechotipatr"
            ],
            "abstract": "Aging is a physiological process that impacts multiple systems of organs. Alzheimer's disease (AD) is the most common form of dementia in the elderly, and it is a major problem in aging societies. The development of AD is linked to an accumulation of amyloid beta and Tau proteins, which impair cognition and cause memory loss.",
            "doi": "10.1186/s12906-025-04881-3",
            "pmid": "40221704",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40221704/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.",
            "authors": [
                "Yajing Zhou",
                "Rory Sheehan",
                "Lizhi Guo",
                "Andre Strydom"
            ],
            "abstract": "Individuals with Down syndrome (DS) are at high risk of Alzheimer's disease (AD), displaying AD pathology similar to the general population. This study evaluated AD-related blood biomarkers in DS within the AT(N) framework through a systematic review and meta-analysis of studies published between 2017 and October 2024. The meta-analysis focused on plasma amyloid beta (Aβ)42, Aβ40, total tau (t-tau), phosphorylated tau (p-tau)181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels, comparing 2109 DS individuals and 1006 euploid controls. Plasma Aβ42, Aβ40, NfL, and GFAP levels were significantly elevated in DS compared to euploid controls, while the Aβ42/40 ratio was reduced. In DS-AD individuals, Aβ42 and t-tau levels were elevated, with p-tau181, NfL, and GFAP consistently high across clinical subgroups. Notably, Aβ40 and the Aβ42/40 ratio changed significantly in preclinical AD, while t-tau increased in clinical AD. Incorporating inflammation (I) markers highlights neuroinflammation's role in DS-AD progression, supporting the blood-based AT(N)I framework for early AD detection and monitoring in DS. HIGHLIGHTS: We reviewed 58 studies on Down syndrome (DS) blood biomarkers and a meta-analysis of 18 using single molecule array. Plasma amyloid beta (Aβ)42, Aβ40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels were elevated in DS compared to controls. DS-Alzheimer's disease (AD) individuals showed higher Aβ42, total tau (t-tau), phosphorylated tau (p-tau)181, NfL, and GFAP levels. Plasma p-tau181, NfL, and GFAP were elevated across all clinical subgroups. Aβ40 and Aβ42/40 ratio changed in preclinical AD; t-tau rose in clinical AD.",
            "doi": "10.1002/alz.70135",
            "pmid": "40219863",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40219863/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Mechanisms Linking Obesity, Insulin Resistance, and Alzheimer's Disease: Effects of Polyphenols and Omega-3 Polyunsaturated Fatty Acids.",
            "authors": [
                "Mahsa Yavari",
                "Nishan Sudheera Kalupahana",
                "Breanna N Harris",
                "Latha Ramalingam",
                "Yujiao Zu",
                "Chanaka Nadeeshan Kahathuduwa",
                "Naima Moustaid-Moussa"
            ],
            "abstract": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and behavioral changes. It poses a significant global health challenge. AD is associated with the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain, along with chronic inflammation, dysfunctional neurons, and synapse loss. While the prevalence of AD continues to rise, the current FDA-approved drugs offer only limited effectiveness. Emerging evidence suggests that obesity, insulin resistance (IR), and type 2 diabetes mellitus (T2DM) are also implicated in AD pathogenesis, with epidemiological studies and animal models confirming the impact of IR on Aβ accumulation, and high-fat diets also exacerbating Aβ accumulation. Since neuroinflammation activated by Aβ involves the nuclear factor kappa-light-chain-enhancer of the activated B cell (NF-κB) pathway, the inhibition of NF-κB and NLRP3 inflammasome activation are potential therapeutic strategies in AD. Bioactive compounds, including polyphenols (resveratrol, epigallocatechin-3-gallate, curcumin, and quercetin), and omega-3 polyunsaturated fatty acids, show promising results in animal studies and clinical trials for reducing Aβ levels, improving cognition and modulating the signaling pathways implicated in AD. This review explores the interplay between obesity, IR, inflammation, and AD pathology, emphasizing the potential of dietary compounds and their role in reducing inflammation, oxidative stress, and cognitive decline, as viable strategies for AD prevention and treatment. By integrating epidemiological findings, observational studies, and clinical trials, this review aims to provide a comprehensive understating of how metabolic dysfunctions and bioactive compounds influence AD progression.",
            "doi": "10.3390/nu17071203",
            "pmid": "40218960",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40218960/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Reevaluating Alzheimer's disease treatment: Can phytochemicals bridge the therapeutic Gap?",
            "authors": [
                "Kishor Kumar Roy",
                "Dinesh Kumar Mehta",
                "Rina Das"
            ],
            "abstract": "Alzheimer's disease (AD) is a growing neurological disorder giving impact cognition and memory, posing a global health challenge with over 55 million individuals affected. It is the 7th foremost cause of dying worldwide, and its pervasiveness is expected to twofold in each five years, reaching 115 million by 2050. AD is characterized by neurofibrillary tangles, senile plaques, and oxidative stress, leading to synaptic failure and cognitive decline. Currently, there is no cure, and available FDA-approved drugs provide only symptomatic relief. The disease progresses through five phases- mild cognitive impairment (MCI), very severe, severe, moderate and mild AD. Research on AD focuses on various neurodegenerative pathways, including inflammation, oxidative stress, genetic factors, environmental variables, and amyloid-beta accumulation. Existing FDA-accepted drugs, like rivastigmine, memantine, galantamine, and donepezil, primarily address early symptoms but have limitations, including side effects and high costs. In this context, phytochemicals from plants, such as resveratrol, huperzine, quercetin, galantamine, and rosmarinic acid, show promise as potential treatments for AD and overcome the challenges and limitation of conventional treatment. These natural substances are being investigated for their ability to lower the risk of AD safely. However, there is a lack of comprehensive knowledge about their application, necessitating further research and clinical trials to explore their potential benefits and limitations. This review serves as an essential reference for advancing future studies on Alzheimer's disease. By thoroughly analyzing neurodegenerative pathways, addressing drug limitations, and highlighting the potential of phytochemicals, we establish a strong foundation for developing innovative therapeutic strategies. Closing the knowledge gap related to the use of phytochemicals in Alzheimer's management is not just important; it is critical for creating novel and more effective treatments for this challenging neurological condition.",
            "doi": "10.1016/j.neuroscience.2025.04.014",
            "pmid": "40216186",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40216186/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Berberine alleviates Alzheimer's disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway.",
            "authors": [
                "Chunbin Sun",
                "Xiaoyu Gao",
                "Shuang Sha",
                "Si Wang",
                "Yubang Shan",
                "Luping Li",
                "Cencan Xing",
                "Hongyan Guan",
                "Hongwu Du"
            ],
            "abstract": "Alzheimer's disease (AD) is a neurodegenerative disease characterized by amyloid beta (Aβ) deposition, phosphorylated Tau protein aggregation, inflammation, and neuronal damage. Neuronal autophagy plays an important role in ameliorating central nervous system diseases such as AD. As an emerging form of iron-dependent cell death, ferroptosis has attracted great attention in the field of neurodegenerative diseases. Berberine (BBR), a natural alkaloid, has demonstrated excellent in inflammation reduction, inhibition of Aβ production, and neuroprotection, making it a potential candidate for AD treatment. However, the mechanisms of autophagy and ferroptosis in BBR treatment of AD have not been elucidated.",
            "doi": "10.1016/j.intimp.2025.114550",
            "pmid": "40215776",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40215776/",
            "source": "pubmed_entrez"
        },
        {
            "title": "The potential of novel gut microbiota supplement in mitigating gut inflammation, alleviating oxidative stress linked to aging, and improving cognitive function in aged mice.",
            "authors": [
                "Kaikwa Wuttisa",
                "Pol Sookpotarom",
                "Benjamaporn Poopan",
                "Chantanapa Chantarangkul",
                "Praewpannarai Jamjuree",
                "Jirapat Namkeaw",
                "Thiranut Jaroonwitchawan",
                "Malai Taweechotipatr"
            ],
            "abstract": "Aging is a physiological process that impacts multiple systems of organs. Alzheimer's disease (AD) is the most common form of dementia in the elderly, and it is a major problem in aging societies. The development of AD is linked to an accumulation of amyloid beta and Tau proteins, which impair cognition and cause memory loss.",
            "doi": "10.1186/s12906-025-04881-3",
            "pmid": "40221704",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40221704/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.",
            "authors": [
                "Yajing Zhou",
                "Rory Sheehan",
                "Lizhi Guo",
                "Andre Strydom"
            ],
            "abstract": "Individuals with Down syndrome (DS) are at high risk of Alzheimer's disease (AD), displaying AD pathology similar to the general population. This study evaluated AD-related blood biomarkers in DS within the AT(N) framework through a systematic review and meta-analysis of studies published between 2017 and October 2024. The meta-analysis focused on plasma amyloid beta (Aβ)42, Aβ40, total tau (t-tau), phosphorylated tau (p-tau)181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels, comparing 2109 DS individuals and 1006 euploid controls. Plasma Aβ42, Aβ40, NfL, and GFAP levels were significantly elevated in DS compared to euploid controls, while the Aβ42/40 ratio was reduced. In DS-AD individuals, Aβ42 and t-tau levels were elevated, with p-tau181, NfL, and GFAP consistently high across clinical subgroups. Notably, Aβ40 and the Aβ42/40 ratio changed significantly in preclinical AD, while t-tau increased in clinical AD. Incorporating inflammation (I) markers highlights neuroinflammation's role in DS-AD progression, supporting the blood-based AT(N)I framework for early AD detection and monitoring in DS. HIGHLIGHTS: We reviewed 58 studies on Down syndrome (DS) blood biomarkers and a meta-analysis of 18 using single molecule array. Plasma amyloid beta (Aβ)42, Aβ40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels were elevated in DS compared to controls. DS-Alzheimer's disease (AD) individuals showed higher Aβ42, total tau (t-tau), phosphorylated tau (p-tau)181, NfL, and GFAP levels. Plasma p-tau181, NfL, and GFAP were elevated across all clinical subgroups. Aβ40 and Aβ42/40 ratio changed in preclinical AD; t-tau rose in clinical AD.",
            "doi": "10.1002/alz.70135",
            "pmid": "40219863",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40219863/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Mechanisms Linking Obesity, Insulin Resistance, and Alzheimer's Disease: Effects of Polyphenols and Omega-3 Polyunsaturated Fatty Acids.",
            "authors": [
                "Mahsa Yavari",
                "Nishan Sudheera Kalupahana",
                "Breanna N Harris",
                "Latha Ramalingam",
                "Yujiao Zu",
                "Chanaka Nadeeshan Kahathuduwa",
                "Naima Moustaid-Moussa"
            ],
            "abstract": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and behavioral changes. It poses a significant global health challenge. AD is associated with the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain, along with chronic inflammation, dysfunctional neurons, and synapse loss. While the prevalence of AD continues to rise, the current FDA-approved drugs offer only limited effectiveness. Emerging evidence suggests that obesity, insulin resistance (IR), and type 2 diabetes mellitus (T2DM) are also implicated in AD pathogenesis, with epidemiological studies and animal models confirming the impact of IR on Aβ accumulation, and high-fat diets also exacerbating Aβ accumulation. Since neuroinflammation activated by Aβ involves the nuclear factor kappa-light-chain-enhancer of the activated B cell (NF-κB) pathway, the inhibition of NF-κB and NLRP3 inflammasome activation are potential therapeutic strategies in AD. Bioactive compounds, including polyphenols (resveratrol, epigallocatechin-3-gallate, curcumin, and quercetin), and omega-3 polyunsaturated fatty acids, show promising results in animal studies and clinical trials for reducing Aβ levels, improving cognition and modulating the signaling pathways implicated in AD. This review explores the interplay between obesity, IR, inflammation, and AD pathology, emphasizing the potential of dietary compounds and their role in reducing inflammation, oxidative stress, and cognitive decline, as viable strategies for AD prevention and treatment. By integrating epidemiological findings, observational studies, and clinical trials, this review aims to provide a comprehensive understating of how metabolic dysfunctions and bioactive compounds influence AD progression.",
            "doi": "10.3390/nu17071203",
            "pmid": "40218960",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40218960/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Omega-3 EPA Supplementation Shapes the Gut Microbiota Composition and Reduces Major Histocompatibility Complex Class II in Aged Wild-Type and APP/PS1 Alzheimer's Mice: A Pilot Experimental Study.",
            "authors": [
                "Barbara Altendorfer",
                "Ariane Benedetti",
                "Heike Mrowetz",
                "Sabine Bernegger",
                "Alina Bretl",
                "Julia Preishuber-Pflügl",
                "Diana Marisa Bessa de Sousa",
                "Anja Maria Ladek",
                "Andreas Koller",
                "Pauline Le Faouder",
                "Justine Bertrand-Michel",
                "Andrea Trost",
                "Ludwig Aigner"
            ],
            "abstract": "<b>Background/Objectives<b>:</b></b> Neuroinflammation, a hallmark of Alzheimer's disease (AD), is characterized by elevated levels of inflammatory signaling molecules, including cytokines and eicosanoids, as well as increased microglial reactivity, and is augmented by gut microbiota dysbiosis via the gut-brain axis. We conducted a pilot experiment to elucidate the anti-inflammatory effects of dietary omega-3 polyunsaturated fatty acid (ω-3 PUFA) eicosapentaenoic acid (EPA) on the gut microbiota and neuroinflammation. <b>Methods</b>: Female APP/PS1 mice (TG) and non-transgenic littermates (WT), 13-14 months old, were fed a diet supplemented with 0.3% EPA or control chow for 3 weeks. The gut microbiota composition, hippocampal and plasma eicosanoids levels, platelet activation, and microglial phagocytosis, as well as the brain and retinal genes and protein expression, were analyzed. <b>Results</b>: EPA supplementation decreased the percentage of <i>Bacteroidetes</i> and increased bacteria of the phylum <i>Firmicutes</i> in APP/PS1 and WT mice. Inflammatory lipid mediators were elevated in the hippocampus of the TG mice, accompanied by a reduction in the endocannabinoid docosahexaenoyl ethanolamide (DHEA). Dietary EPA did not affect hippocampal lipid mediators, but reduced the levels of arachidonic-derived 5-HETE and <i>N</i>-arachidonoylethanolamine (AEA) in WT plasma. Moreover, EPA supplementation decreased major histocompatibility complex class II (MHCII) gene expression in the retina in both genotypes, and MHCII+ cells in the hippocampus of TG mice. <b>Conclusions</b>: This pilot study showed that short-term EPA supplementation shaped the gut microbiota by increasing butyrate-producing bacteria of the <i>Firmicutes</i> phylum and decreasing Gram-negative LPS-producing bacteria of the <i>Bacteroidetes</i> phylum, and downregulated the inflammatory microglial marker MHCII in two distinct regions of the central nervous system (CNS). Further investigation is needed to determine whether EPA-mediated effects on the microbiome and microglial MHCII have beneficial long-term effects on AD pathology and cognition.",
            "doi": "10.3390/nu17071108",
            "pmid": "40218866",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40218866/",
            "source": "pubmed_entrez"
        },
        {
            "title": "Reevaluating Alzheimer's disease treatment: Can phytochemicals bridge the therapeutic Gap?",
            "authors": [
                "Kishor Kumar Roy",
                "Dinesh Kumar Mehta",
                "Rina Das"
            ],
            "abstract": "Alzheimer's disease (AD) is a growing neurological disorder giving impact cognition and memory, posing a global health challenge with over 55 million individuals affected. It is the 7th foremost cause of dying worldwide, and its pervasiveness is expected to twofold in each five years, reaching 115 million by 2050. AD is characterized by neurofibrillary tangles, senile plaques, and oxidative stress, leading to synaptic failure and cognitive decline. Currently, there is no cure, and available FDA-approved drugs provide only symptomatic relief. The disease progresses through five phases- mild cognitive impairment (MCI), very severe, severe, moderate and mild AD. Research on AD focuses on various neurodegenerative pathways, including inflammation, oxidative stress, genetic factors, environmental variables, and amyloid-beta accumulation. Existing FDA-accepted drugs, like rivastigmine, memantine, galantamine, and donepezil, primarily address early symptoms but have limitations, including side effects and high costs. In this context, phytochemicals from plants, such as resveratrol, huperzine, quercetin, galantamine, and rosmarinic acid, show promise as potential treatments for AD and overcome the challenges and limitation of conventional treatment. These natural substances are being investigated for their ability to lower the risk of AD safely. However, there is a lack of comprehensive knowledge about their application, necessitating further research and clinical trials to explore their potential benefits and limitations. This review serves as an essential reference for advancing future studies on Alzheimer's disease. By thoroughly analyzing neurodegenerative pathways, addressing drug limitations, and highlighting the potential of phytochemicals, we establish a strong foundation for developing innovative therapeutic strategies. Closing the knowledge gap related to the use of phytochemicals in Alzheimer's management is not just important; it is critical for creating novel and more effective treatments for this challenging neurological condition.",
            "doi": "10.1016/j.neuroscience.2025.04.014",
            "pmid": "40216186",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40216186/",
            "source": "pubmed_entrez"
        }
    ],
    "aggregated_context": "**1. Analizowany Temat:**\n\nTekst wejściowy opisuje relację między stanem zapalnym (zapaleniem), peptydem amyloid beta (Aβ) i chorobą Alzheimera (ChA).  Głównym tematem jest rola zapalenia w patogenezie ChA poprzez wpływ na akumulację Aβ.\n\n**2. Kluczowe Definicje:**\n\n- **Zapalenie:** Biologiczna odpowiedź tkanek ciała na szkodliwe bodźce, takie jak patogeny, uszkodzone komórki lub substancje drażniące. Obejmuje aktywację komórek immunologicznych, rozszerzenie naczyń krwionośnych i uwalnianie różnych cząsteczek promujących gojenie.\n- **Amyloid Beta (Aβ):** Peptyd produkowany w mózgu w wyniku rozpadu większego białka zwanego prekursorem białka amyloidowego (APP). Akumulacja Aβ w mózgu jest powszechnie związana z chorobami neurodegeneracyjnymi, zwłaszcza z chorobą Alzheimera.\n- **Choroba Alzheimera (ChA):** Postępujące zaburzenie neurologiczne charakteryzujące się pogorszeniem funkcji poznawczych, utratą pamięci oraz zmianami w zachowaniu i osobowości. Jest związane z gromadzeniem się płytek amyloidowych Aβ i splątkami neurofibrylarnymi w mózgu.\n\n**3. Główne Powiązania/Mechanizmy Opisane w Tekście Wejściowym:**\n\n- **Zapalenie zwiększa Amyloid Beta:** Obecność stanu zapalnego w mózgu może prowadzić do zwiększenia produkcji lub agregacji peptydów Aβ.  Sugeruje to, że procesy zapalne mogą odgrywać kluczową rolę w patogenezie choroby Alzheimera, wzmacniając toksyczne działanie Aβ.\n- **Amyloid Beta kumuluje się w chorobie Alzheimera:**  Akumulacja Aβ jest charakterystyczną cechą choroby Alzheimera. U chorych obserwuje się znaczne nagromadzenie płytek amyloidowych Aβ w mózgu, co uważa się za przyczyniające się do procesów neurodegeneracyjnych, takich jak dysfunkcja synaptyczna i śmierć neuronów.\n\n**4. Kontekst z Literatury Naukowej:**\n\nLiteratura naukowa potwierdza silny związek między zapaleniem, Aβ i ChA.  Badania wskazują na podwyższone poziomy Aβ i innych biomarkerów (np. tau, NfL, GFAP) we krwi osób z ChA, a także u osób z zespołem Downa, które są predysponowane do rozwoju ChA.  Wspomniano o roli zaburzeń metabolicznych (otyłość, insulinooporność) w patogenezie ChA poprzez wpływ na akumulację Aβ i nasilenie stanów zapalnych.  Badania eksplorują potencjalne strategie terapeutyczne, takie jak wykorzystanie polifenoli i kwasów tłuszczowych omega-3, które mogą redukować stany zapalne i poziomy Aβ.  Zauważono również rolę autofagii i ferroptozy w rozwoju ChA oraz potencjalne korzyści z modulowania tych procesów.  Niektóre badania wskazują na wpływ mikrobioty jelitowej na stan zapalny i funkcje poznawcze, sugerując potencjalne zastosowanie suplementów probiotycznych.\n\n**5. Kontekst z Ogólnego Internetu:**\n\nBrak wyników z wyszukiwania w internecie.\n\n**6. Synteza i Wnioski Ogólne:**\n\nAnaliza tekstu wejściowego, w połączeniu z informacjami z literatury naukowej, wskazuje na złożoną interakcję między zapaleniem, akumulacją Aβ i rozwojem choroby Alzheimera.  Zapalenie odgrywa znaczącą rolę w patogenezie choroby, nasilając toksyczne działanie Aβ.  Literatura naukowa dostarcza dowodów na  istnienie licznych biomarkerów ChA i bada potencjalne metody terapeutyczne ukierunkowane na redukcję stanów zapalnych i poziomu Aβ.  Wyniki badań sugerują, że dalsze badania nad interakcjami między mikrobiotą jelitową, metabolizmem i mózgiem są niezbędne dla pełnego zrozumienia i opracowania skutecznych terapii choroby Alzheimera."
}